Juno Therapeutics, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GPRC5DCell therapy
Multiple Myeloma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Arlocabtagene autoleucelPhase 3Relapsed or Refractory Multiple Myeloma (RRMM)
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultarlocabtagene autoleucelRegistrational Phase 2 QUINTESSENTIAL (NCT06297226) met its primary endpoint
Bristol-Myers Squibb · Source ↗

Financial reports

No financial reports recorded.